Novo Nordisk has submitted a third application to have its weight-loss drug Wegovy subsidised under Australia's Pharmaceutical Benefits Scheme, this time targeting overweight or obese patients with cardiovascular disease.
Breakdown
- Novo Nordisk has submitted a third application to list Wegovy on the PBS.
- Previous applications were rejected due to concerns about the cost to the health system. 13s
- The latest submission targets overweight or obese patients with cardiovascular disease. 28s
- Wegovy currently costs between $345 and $645 per month. 35s
- The Pharmaceutical Benefits Advisory Committee will consider the submission in early November. 41s